3-amino-4-methylthiopyridine | 38240-24-3

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 3-amino-4-methylthiopyridine
• 英文别名: 3-Amino-4-methylthiopyridin；4-methylsulfanyl-pyridin-3-ylamine；4-methylsulfanyl-[3]pyridylamine；4-Methylmercapto-[3]pyridylamin；4-(Methylsulfanyl)pyridin-3-amine；4-methylsulfanylpyridin-3-amine
• CAS: 38240-24-3
• 化学式: C₆H₈N₂S
• mdl: MFCD11635404
• 分子量: 140.209
• InChiKey: IMJRXBSOKCHICY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  64.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-amino-4-methylthiopyridine 在 potassium carbonate 、 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 16.0h， 生成
  参考文献：
  名称：

  ACAT inhibitors derived from hetero-Diels-Alder cycloadducts of thioaldehydes

  摘要：

  Acyl-CoA:cholesterol acyltransferase (ACAT) is the enzyme largely responsible for intracellular cholesterol esterification. A systemic inhibitor of ACAT is believed to be able to slow or even reverse the atherosclerotic process. Towards that goal, a series of cyclic sulfides, derived from the hetero-Diels-Alder reaction of thioaldehydes with 1,3-dienes, and bearing carboxamide substituents, were prepared and evaluated for in vitro (in several tissues and species) and ex vivo ACAT inhibition. Minor changes in subsequent structure were found to have a significant effect in optimization of the biological activity of this series of compounds. Copyright (C) 1996 The DuPont Merck Pharmaceutical Company.

  DOI：

  10.1016/0968-0896(96)00143-5
• 作为产物：
  描述：

  3-nitro-4-thiocyanato-pyridine 在 盐酸 、 氢氧化钾 、 乙醇 、 水 、 tin(ll) chloride 作用下， 生成 3-amino-4-methylthiopyridine
  参考文献：
  名称：

  Takahashi et al., Pharmaceutical Bulletin, 1954, vol. 2, p. 196,200

  摘要：

  DOI：

文献信息

• Cephalosporin compounds, and their production, and medicaments containing them
  申请人：YAMANOUCHI PHARMACEUTICAL CO. LTD.

  公开号：EP0160546A2

  公开（公告）日：1985-11-06

  This invention relates to antibacterial cephalosporin compounds, to the production of these compounds, and to medical compositions containing them. The compounds of this invention are those of the general formula I and salts thereof: wherein R1 represents a lower alkyl group which may be substituted by a carboxyl group; R2 and R3, which may be the same or different, each represents an amino group, a lower alkyl group, a lower alkylthio group, or a lower alkoxy group which may be substituted by hydroxyl group(s) and or amino group(s), or R2 and R3 combine to form wherein R4 represents a hydrogen atom, a hydroxyl group, or a lower alkoxy group; A represents a direct linkage or a carbonyl group; and m represents an integer of 1 to 2.

  本发明涉及抗菌头孢菌素化合物、这些化合物的生产以及含有这些化合物的医用组合物。本发明的化合物为通式 I 及其盐类： 其中 R1 代表可被羧基取代的低级烷基； R2和R3可以相同或不同，各自代表氨基、低级烷基、低级烷硫基或可被羟基和或氨基取代的低级烷氧基，或R2和R3结合形成 其中 R4 代表氢原子、羟基或低级烷氧基；A 代表直接连接或羰基；m 代表 1 至 2 的整数。
• [EN] NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF<br/>[FR] RÉGULATEUR DÉRIVÉ HÉTÉROCYCLIQUE CONTENANT DE L'AZOTE, SON PROCÉDÉ DE PRÉPARATION ET SON APPLICATION<br/>[ZH] 含氮杂环类衍生物调节剂、其制备方法和应用
  申请人：SHANGHAI HANSOH BIOMEDICAL CO LTD

  公开号：WO2020239077A1

  公开（公告）日：2020-12-03

  公开了一种含氮杂环类衍生物调节剂、其制备方法和应用。特别地，公开了通式(I)所示的化合物、其制备方法及含有该化合物的药物组合物，及其作为KRAS G12C突变抑制剂，在治疗白血病、神经母细胞瘤、黑色素瘤、乳腺癌、肺癌及其结肠癌等疾病或病症的用途，其中通式(I)中的各取代基与说明书中的定义相同。
• 2-AMINOBENZIMIDAZOLE-5-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2403852B1

  公开（公告）日：2014-10-29
• Barlin, Journal of the Chemical Society
  作者：Barlin

  DOI：——

  日期：——
• ACAT inhibitors derived from hetero-Diels-Alder cycloadducts of thioaldehydes
  作者：Richard G. Wilde、Jeffrey T. Billheimer、Sandie J. Germain、Elizabeth A. Hausner、Paul C. Meunier、Deborah A. Munzer、Janet K. Stoltenborg、Peter J. Gillies、Deborah L. Burcham、Shiew-Mai Huang、John D. Klaczkiewicz、Soo S. Ko、Ruth R. Wexler

  DOI：10.1016/0968-0896(96)00143-5

  日期：1996.9

  Acyl-CoA:cholesterol acyltransferase (ACAT) is the enzyme largely responsible for intracellular cholesterol esterification. A systemic inhibitor of ACAT is believed to be able to slow or even reverse the atherosclerotic process. Towards that goal, a series of cyclic sulfides, derived from the hetero-Diels-Alder reaction of thioaldehydes with 1,3-dienes, and bearing carboxamide substituents, were prepared and evaluated for in vitro (in several tissues and species) and ex vivo ACAT inhibition. Minor changes in subsequent structure were found to have a significant effect in optimization of the biological activity of this series of compounds. Copyright (C) 1996 The DuPont Merck Pharmaceutical Company.